Rationale: Binding of maternal anti-Ro/La antibodies to cognate antigen expressed on apoptotic cardiocytes decreases clearance by healthy cardiocytes, which may contribute to the development of autoimmune associated congenital heart block and fatal cardiomyopathy. Objective: Given recent evidence implicating the urokinase plasminogen activator receptor (uPAR) as a "don't eat me" signal during efferocytosis, experiments addressed whether surface bound anti-Ro antibodies inhibit apoptotic cell removal via an effect on the expression/function of the urokinase-type plasminogen activator protease (uPA)/uPAR system. Key Words: congenital heart block Ⅲ anti-SSA/Ro60 Ⅲ uPA/uPAR Ⅲ apoptosis C ongenital heart block (CHB), absent structural abnormalities, is a fetal disorder that is almost universally associated with maternal antibodies to the ribonucleoproteins SSA/Ro and SSB/La. 1 In contrast to autoimmune diseases affecting the blood elements in which the target antigen is normally accessible to the cognate antibody by virtue of its surface expression, CHB presents a molecular challenge in that the target antigens are located intracellularly. Apoptosis has been posited as a means by which these normally inaccessible antigens can be trafficked to the cell membrane. [2] [3] [4] [5] [6] Support for this mechanism has been generated in several laboratories by the demonstration of antibody binding to all 3 components of the SSA/Ro-SSB/La system, including 48-kDa La, 52-kDa Ro, and 60-kDa Ro, on the surface of apoptotic keratinocytes 2,7 and human fetal cardiocytes. 8 Apoptosis may be particularly relevant in the pathogenesis of CHB because it is a selective process of physiological cell deletion in embryogenesis and normal tissue turnover and plays an important role in shaping morphological and functional maturity. 9 -11 It is generally accepted that apoptotic cells are rapidly removed to obviate any inflammatory sequelae. To achieve efficient clearance, human fetal cardiocytes are capable of engulfing apoptotic cardiocytes. 5 This novel physiological function may account for the nearly complete absence of apoptosis noted on evaluation of healthy hearts from electively terminated fetuses. 12 However, histological studies of hearts from fetuses dying with CHB reveal exaggerated apoptosis, suggesting a potential defect in clearance. 12 These histological findings are supported by in vitro experiments which demonstrate that antibodies to SSA/Ro -SSB/La inhibit cardiac uptake of apoptotic cardiocytes. 5 The abnormal persistence of opsonized apoptotic cardiocytes diverts their removal by healthy cardiocytes to removal by infiltrating macrophages which results in release of proinflammatory and profibrosing cytokines culminating in transdifferentiation of cardiac fibroblasts and subsequent replacement of healthy conducting tissue with scar. 3, 4, 12 
C ongenital heart block (CHB), absent structural abnormalities, is a fetal disorder that is almost universally associated with maternal antibodies to the ribonucleoproteins SSA/Ro and SSB/La. 1 In contrast to autoimmune diseases affecting the blood elements in which the target antigen is normally accessible to the cognate antibody by virtue of its surface expression, CHB presents a molecular challenge in that the target antigens are located intracellularly. Apoptosis has been posited as a means by which these normally inaccessible antigens can be trafficked to the cell membrane. [2] [3] [4] [5] [6] Support for this mechanism has been generated in several laboratories by the demonstration of antibody binding to all 3 components of the SSA/Ro-SSB/La system, including 48-kDa La, 52-kDa Ro, and 60-kDa Ro, on the surface of apoptotic keratinocytes 2, 7 and human fetal cardiocytes. 8 Apoptosis may be particularly relevant in the pathogenesis of CHB because it is a selective process of physiological cell deletion in embryogenesis and normal tissue turnover and plays an important role in shaping morphological and functional maturity. 9 -11 It is generally accepted that apoptotic cells are rapidly removed to obviate any inflammatory sequelae. To achieve efficient clearance, human fetal cardiocytes are capable of engulfing apoptotic cardiocytes. 5 This novel physiological function may account for the nearly complete absence of apoptosis noted on evaluation of healthy hearts from electively terminated fetuses. 12 However, histological studies of hearts from fetuses dying with CHB reveal exaggerated apoptosis, suggesting a potential defect in clearance. 12 These histological findings are supported by in vitro experiments which demonstrate that antibodies to SSA/Ro -SSB/La inhibit cardiac uptake of apoptotic cardiocytes. 5 The abnormal persistence of opsonized apoptotic cardiocytes diverts their removal by healthy cardiocytes to removal by infiltrating macrophages which results in release of proinflammatory and profibrosing cytokines culminating in transdifferentiation of cardiac fibroblasts and subsequent replacement of healthy conducting tissue with scar. 3, 4, 12 The mechanism by which maternal autoantibodies impair clearance of apoptotic cardiocytes has yet to be determined but is likely to provide a pivotal clue to the pathogenesis of CHB. In considering molecular changes that might be induced by binding of anti-SSA/Ro antibodies to the apoptotic surface, the urokinase plasminogen activator receptor (uPAR) is a potential candidate because it has been recently reported to play a role in efferocytosis and recognition of apoptotic cell clearance. Specifically, uPAR has been identified as a "don't eat me" signal on apoptotic cells and as a receptor for engulfing the apoptotic corpse. [13] [14] [15] uPAR is an important part of the plasminogen activation system. Urokinase-type plasminogen activator (uPA) was the first identified ligand of uPAR 16 ; thus, the major role of uPAR was thought to be in the regulation of pericellular proteolysis through the activation of plasminogen to active plasmin. However, recent studies have shown that uPA binding to uPAR plays a pivotal role in signaling functions that influence cell behavior. 17 In addition, being a glycosyl-phosphatidylinositol (GPI)-anchored protein, uPAR can interact laterally with a wide variety of membrane proteins including integrins, endocytic receptors, caveolin, the gp130 cytokine receptor, the EGF receptor, and FPRL1 (FPR-like receptor-1), a classic chemoattractant receptor. 18 -22 These interactions underline the importance of uPAR, despite its absence of an intracellular domain, in many cellular events, including adhesion, migration, growth, and regulation of apoptotic clearance. The function of the uPA/uPAR system appears to be cell typespecific and a particular relevance has been highlighted in the heart, 23 uPA knockout mice are resistant to cardiac fibrosis, 24, 25 whereas mice with increased uPA-dependent plasminogen activity develop cardiac fibrosis. 14,15,26 -28 Because exaggerated apoptosis of human fetal cardiocytes appears to be an essential link between maternal autoantibodies and cardiac tissue damage, the present study was initiated to investigate the hypothesis that the uPA/uPAR system is involved in the inhibition of efferocytosis induced by anti-SSA/Ro-SSB/La binding. The experimental approach addressed the effect of maternal antibody binding to different components of the SSA/Ro-SSB/La complex on apoptotic human fetal cardiocytes and subsequent uPAR expression and modulation. Functional readouts included efferocytosis of apoptotic cardiocytes by healthy cardiocytes and measurement of cell surface uPA activation.
Methods

Materials
The following commercial antibodies were used: mouse monoclonal anti-uPAR (no. 3936) and rabbit polyclonal anti-uPA (no. 389) were from American Diagnostica (Stamford, Conn), and rabbit polyclonal anti-uPAR (FL-290) was from Santa Cruz Biotechnology (Santa Cruz, Calif). Mouse monoclonal anti-␣-actin clone AC-15 (A19780), mouse monoclonal ␣-sarcomeric actinin (A7811), and mouse monoclonal anti-HLA were from Sigma-Aldrich, (St Louis, Mo). Mouse monoclonal IgG2A (Clone 20102) was from R&D systems (Minneapolis, Minn). Mouse monoclonal antibodies against CD31, CD47, and calreticulin were from BD Transduction Laboratories (San Jose, Calif). Spectrozyme PL (chromogenic substrate of plasmin), human 2-chain uPA and human glu-plasminogen were obtained from American Diagnostica. ␤ 2 GPI was from Hematologic Technologies (Essex Junction, Vt). Secondary antibodies used for microscopy were Alexa Fluor-488, Alexia Fluor-568 from Invitrogen (Carlsbad, Calif), horseradish peroxidase-conjugated secondary antibodies from Santa Cruz Biotechnology (Santa Cruz, Calif), and fluorescein isothiocyanate (FITC)-conjugated secondary antibodies from Sigma. Staurosporine was purchased from MP Biomedicals (Solon, Ohio). Crosslinker DTSSP was obtained from Thermo Scientific (Waltham, Mass).
Preparation of IgG Fractions From Healthy Controls and Patients and Affinity-Purified Human Antibodies and Chicken Monoclonal Antibodies
IgG fractions, affinity-purified antibodies against Ro60, Ro52, La48, and chicken monoclonal anti-Ro60, anti-Ro52, and anti-La48 antibodies were prepared as previously described. 5, 6 Briefly, using a Protein A-IgG isolation kit (no. 20356; Pierce Biotechnology, Rockford, Ill), human IgG was isolated from the serum of a healthy donor (nl-IgG), as well as from 3 mothers whose sera contain antibodies to all components of the SSA/Ro-SSB/La complex and whose children have CHB (CHB-IgG). For some experiments, IgG was isolated from a patient with Systemic Lupus Erythematosus with high titer antibodies to RNP absent antibodies to SSA/Ro or SSB/La (RNP-IgG). CHB-IgG was used to obtain affinity-purified antiRo60, anti-Ro52, and anti-La48 by affinity column chromatography using recombinant proteins (Ro60, Ro52, La48, respectively) coupled to CNBr-activated Sepharose 4B. Eluted antibodies were neutralized with 1 mol/L Tris and tested for specificity by ELISA. Protein concentrations of affinity-purified antibodies and IgG fractions were assessed using a protein quantification kit (Pierce Biotechnology). For preparation of chicken monoclonal single-chain variable fragment (ScFv) antibodies, clones previously constructed 5 were grown in hosts that generate soluble ScFv antibodies and subsequently confirmed to have monoclonal reactivity to the respective recombinant antigen. 5 Both ScFv1 and ScFv2 recognize intracellular Ro60 but only ScFv1 binds apoptotic cells. 5 ScFv48 and ScFv52 were similarly constructed exhibiting specificity toward La48 and Ro52, respectively.
Cell Cultures
Human fetal cardiocytes were cultured as previously described. [3] [4] [5] [6] 12 Specifically, cardiocytes of gestational ages 16 to 24 weeks were aseptically obtained after elective termination of normal pregnancy in accordance with the guidelines of the Institutional Review Board of New York University School of Medicine and after obtaining consent from the mothers (tissue is obtained from the Human Fetal Tissue Repository of the Albert Einstein College of Medicine). More than 75% of the cells were reactive with a murine monoclonal anti-␣-sarcomeric actinin antibody, which stains Z lines and dots in stress fibers of skeletal and cardiac muscle but not in nonsarcomeric muscle elements such as connective tissue, epithelium, nerves, or smooth muscle. Cells were cultured in DMEM supplemented with 10% FBS, 50 U/mL penicillin, 50 U/mL streptomycin, 100 mg/mL gentamicin, 1 mmol/L nonessential amino acid (Life Technologies), 0.1 mmol/L essential medium vitamins (Life Technologies), 2 mmol/L glutamine, and 0.1 mmol/L sodium pyruvate) in 5% CO2 at 37°C. Interdonor variability of uPAR expression on the primary fetal cardiocytes based on immunoblot, immunofluorescence, and flow cytometry was observed (Ϸ30%), as reported by others (see elsewhere 29, 30 and Dr Audrey Bernstein, personal communication). In addition, the expression of uPAR was diminished during passage 2 and 3 and maintenance in culture compared to passage 1 isolated cardiocytes (approximately 60% reduction). Accordingly, only passage 1 cardiocytes were used in all studies described herein and plated immediately before experimentation.
Human macrophages derived from peripheral blood mononuclear cells were isolated from WBC concentrate (Leukopak; New York Blood Center) by centrifugation on Ficoll-Hypaque gradients and purified by positive selection using CD14 microbeads (Miltenyi Biotech, catalog no. 130-050-201, Miltenyi Biotech, Auburn, Calif) and LS columns (Miltenyi Biotech, catalog no. 130-042-401). The resulting monocytes were then cultured in Teflon beakers (RPMI 1640/10% FCS plus 10 ng/mL GM-CSF; PHC2014, Invitrogen, San Diego, Calif) for 7 days. Monocyte-derived macrophages (5ϫ105 per milliliter) were plated on growth medium containing 10% serum and incubated at 37°C.
Activation of Apoptotic Pathway in Human Fetal Cardiocytes
For induction of apoptosis, cardiocytes were transferred to serumfree media containing 0.5% BSA (Sigma-Aldrich, Sydney, Australia) and 0.5 mol/L staurosporine for 5 hours at 37°C, followed by washing and further incubation in medium for 12 hours. Apoptosis was confirmed by microscopic observation of cell size, morphology, and flow cytometric analysis of phosphadylserine exposure by binding of Annexin V-FITC (catalog no. 556419, BD Pharmingen; 1:50) according to the recommendations of the manufacturer.
Immunostaining, Immunoprecipitation, and Crosslinking Studies
For immunoblot analysis, cells were collected from culture dishes, washed 3 times in PBS, and lysed in solubilization buffer (50 mmol/L Hepes, pH 7.4, buffer containing 0.1% Triton X-100, 10% glycerol, 0.5% deoxycholic acid, 150 mmol/L NaCl, 50 mmol/L NaF, 1 mmol/L NaVO4, 100 g/mL phenylmethylsulfonyl fluoride, 2 g/mL leupeptin, 2 g/mL pepstatin, and 10 g/mL aprotinin) for 30 minutes at 4°C. Healthy cells were routinely collected by gentle scraping to avoid cleavage of surface uPAR. The lysates were centrifuged at 15 000 rpm for 15 minutes at 4°C and protein content was measured using a Bio-Rad protein assay kit, with serum albumin as a standard. Lysate (20 g) was subjected to SDS-PAGE under reducing or nonreducing conditions and transferred onto nitrocellulose membranes. The membranes were blocked with 1% BSA in wash buffer for 1 hour at room temperature (RT), followed by an overnight incubation with the appropriate antibodies in the same buffer at 4°C. The membranes were subsequently washed and secondary horseradish peroxidase-conjugated antibodies were added. Proteins were detected using the ECL chemiluminescent detection reagents (Invitrogen) according to the instructions of the manufacturer. Where appropriate, membranes were stripped with ␤-mercaptoethanol and subjected to Western blotting for ␣-actin.
For immunoprecipitation experiments, cells were collected, washed in PBS, and lysed in lysis buffer. Cell proteins (1 to 1.5 mg) were incubated with the appropriate antibody (0.5 g/mL) for 2 hours at 4°C under gentle agitation; then, protein A-Sepharose (5 mg/mL) was added. After shaking for 30 minutes at 4°C, the solid-phase resin binding the antigen/antibody was recovered by centrifugation and thoroughly washed 5 times with the buffer (50 mmol/L Hepes, 150 mmol/L NaCl, 10% glycerol, 0.5% DOC, 1% Triton X-100) solution. After adding loading buffer, the samples were analyzed by immunoblot as described above.
For crosslinking studies, apoptotic cardiocytes were washed in serum-free DMEM (containing 2% BSA, 20 mmol/L Hepes, pH 7.4), and bound proteins were crosslinked using the thiol cleavable crosslinker DTSSP (1 mmol/L) (Pierce) for 15 minutes at 4°C. The reaction was quenched with Tris-buffered saline for 10 minutes at 4°C and lysates were prepared as described above.
Flow Cytometry
For the detection of surface proteins via flow cytometry, healthy and apoptotic cells were collected from culture vessels (healthy cells were gently scraped to avoid cleavage of surface proteins) washed 2 times with staining buffer (ice-cold PBS containing 5% normal goat serum) and resuspended in 200 L of staining buffer containing the appropriate primary antibody. CHB-IgG, RNP-IgG, and nl-IgG were used at a concentration of 0.3 mg/mL, affinity-purified anti-Ro60, -Ro52, and -La48 antibodies were used at 15 g/mL; monoclonal ScFvs were used at 15 g/mL; and commercial antibodies were used at 1 g/mL. Cells were incubated at RT for 1 hour with intermittent mixing, washed 3 times with staining buffer and resuspended in 200 L of FITC-conjugated secondary antibodies in the ratio of 1:100, and incubated in the dark at RT for 1 hour. Cells suspensions were analyzed (104 cells per tube) with a FACScan flow cytometer using CellQuest software as per the instructions of the manufacturer (Becton Dickinson, San Jose, Calif).
Immunofluorescence
Immunodetection was performed on cells after fixation with 3% paraformaldehyde (Fisher Scientific, Fair Lawn, NJ) in PBS (pH 7.4) for 15 minutes at RT. For detection of ␣-sarcomeric actinin, cells were acetone fixed for 5 minutes at RT. After nonspecific binding was blocked with 3% normal goat serum (Jackson ImmunoResearch, West Grove, Pa), cells were incubated with the appropriate primary antibodies and then with secondary antibodies, either anti-mouse, anti-human, or anti-rabbit IgG Alexa Fluor dyes 488 and 568 (Molecular Probes) at RT. Cells were then stained with 2 g/mL Hoechst 33258 for 30 minutes at 37°C and embedded in Vectashield mounting medium (Vector Laboratories). The nuclei stained with Hoechst 33258 that were markedly bright and small or divided into several homologous chromatin clumps were defined as being condensed or fragmented nuclei, respectively. For each sample at least 6 images from 5 independent experiments were analyzed. Cells were routinely not Triton X-permeabilized before staining for uPAR to avoid extraction of GPI-linked uPAR.
Cells were viewed with 1 of 2 microscopes (Axioplan, Carl Zeiss Meditec, Thornwood, NY; or a laser-scanning confocal microscope, Leica, Wetzlar, Germany), as indicated. For the Axioplan, images were captured with a charge-coupled device camera (SPOT-2; Diagnostic Instruments, Sterling Heights, Mich; processed by PhotoShop; Adobe Systems, Mountain View, Calif). The images were subsequently combined and processed with ImageJ software (NIH, Bethesda, Md; http://rsb.info.nih.gov/ij).
uPA Activity Assay uPA activation was determined using a chromogenic assay. Apoptotic cardiocytes were treated with the following antibodies: CHB-IgG, nl-IgG, ScFv1, and ScFv2 for 30 minutes at RT. In separate experiments, anti-uPA, anti-uPAR, and isotype control antibodies were added either alone or following preincubation with nl-IgG or CHB-IgG. Additional experimental conditions included preincubation of apoptotic cardiocytes with ␤ 2 GPI (5 g/mL) alone or preincubation with ␤ 2 GPI and subsequent treatment with either nl-IgG or CHB-IgG. Cells were then washed, resuspended in PBS/0.1% BSA, and plated in triplicate in a volume of 115 L/ density of 2ϫ103 cells/well of a 96-well plate. Ten microliters of human plasminogen (0.2 mg/mL in PBS) was added, and after a 2-hour incubation at 37°C, 15 L of chromogenic substrate for plasmin (Spectrozyme PL) was added to each well. The chromogenic substrate was prepared by diluting 50 mol into 27 mL of lysis buffer and then neutralized to pH 7.0 with 0.6 mL of 1 N HCl. The reaction product was read on a Bio-Tek spectrophotometer (405 nm; Bio-Tek Instruments, Winooski, Vt) at 1 hour, and the results were compared with a standard curve that was produced by serial dilutions of high-molecular-weight uPA. Controls included PBS/0.1% BSA buffer alone and samples absent plasminogen.
Engulfment Assay
Healthy human fetal cardiocytes were plated on 4-well chamber slides (10 000/well) (Becton Dickinson). A total of 3 to 5ϫ106 healthy cardiocytes were rendered apoptotic (treated as described below) and added to cultured healthy cardiocytes to achieve a ratio of 2:1 apoptotic cells:healthy cardiocytes (5 hours), followed by washing to remove nonadherent apoptotic cells. The remaining apoptotic cells, which were engulfed by intact cardiocytes, were treated with TUNEL reagents (Roche Diagnostics) to aid in their identification. Cell preparations were analyzed after staining using a secondary peroxidase-labeled antibody (also included in the TUNEL kit). Engulfment was scored using a light microscope, and for each stain, 100 cells were examined in each duplicate well, and the number of cells that stained positive were then averaged. A cell was considered positive for engulfment if it had internalized a TUNELpositive cell. The percentage of cells involved in engulfment of apoptotic cells was determined by dividing the number of cells with internalized apoptotic cells by the total number of cells. 5 Before addition, the apoptotic cardiocytes in a total volume of 1 mL of DMEM plus 10% FCS were preincubated with various antibody preparations, which included the following: CHB-IgG (0.3 mg/mL), nl-IgG (0.3 mg/mL), ScFv monoclonal antibodies (15 g/mL), mouse anti-uPAR (1 g/mL) (American Diagnostica); rabbit anti-uPAR (1 g/mL) (Santa Cruz Biotechnology); and anti-HLA (1 g/mL) (Sigma-Aldrich). In 1 set of experiments, nl-IgG, CHB-IgG, ScFv1, or ScFv2 was added to apoptotic cardiocytes before the addition of anti-uPAR antibodies. In separate experiments, ScFv1 antibody was added before the addition of anti-HLA antibody. For evaluation of antibody binding, a proportion of the apoptotic cells were directly stained with the appropriate secondary or tertiary antibodies and then analyzed by FACScan.
Statistics
For statistical analysis, the t test (paired or unpaired used as appropriate) was used to compare means between groups in the engulfment and plasminogen assays and the Mann-Whitney U test to compare medians of fluorescence-activated cell-sorting (FACS) fluorescence measurements between the different groups and PϽ0.05 was considered statistically significant. Analyses were performed with GraphPad Prism (GraphPad Software, San Diego, Calif).
Results uPAR Is Expressed on the Surface of Healthy Fetal Cardiocytes
Initial experiments addressed the surface expression of uPAR on the cultured human fetal cardiocytes. Based on immunoblot of whole-cell lysates, cardiocytes express uPAR ( Figure  1A ). Whole-cell lysates of human macrophages were used as a positive control because uPAR is present on peripheral blood mononuclear cells from healthy donors. 31 Furthermore, flow cytometry of viable nonpermeabilized fetal cardiocytes demonstrated surface expression of uPAR (39Ϯ5 mean fluorescence units [MFU] isotype control versus 58Ϯ12 MFU anti-uPAR; Pϭ0.01, nϭ5) ( Figure 1B ). As expected, CHBIgG did not bind the viable cardiocytes (39Ϯ5 MFU nl-IgG versus 41Ϯ12 MFU CHB-IgG; Pϭ0.7, nϭ5) ( Figure 1B ). 5, 6 Surface expression of uPAR (red speckles) and nuclear localization of Ro60 assessed by affinity-purified anti-Ro60 (green) ( Figure 1C ) were reported in fixed cardiocytes. The isotype control condition stained appropriately ( Figure 1D ). The uPAR-positive cells also expressed ␣-sarcomeric actinin confirming the cell type as cardiac myocytes ( Figure 1E ). 29, 32 uPAR Colocalizes With Ro60 on the Cell Surface of Apoptotic Cells
The expression of uPAR and its relationship to Ro60 were evaluated on the apoptotic cardiocytes. Apoptosis was induced by incubation with staurosporine and confirmed by Annexin V staining. Surface expression of uPAR was demonstrated (34Ϯ12 MFU isotype control versus 62Ϯ19 MFU anti-uPAR; Pϭ0.05, nϭ5). In contrast to viable cells, the apoptotic cardiocytes expressed SSA/Ro-SSB/La on the cell surface (37Ϯ7 MFU nl-IgG versus 72Ϯ12 MFU CHB-IgG, Pϭ0.003, nϭ5) (Figure 2A ). uPAR and SSA/ Ro-SSB/La were colocalized to the membrane within (yellow) structures resembling apoptotic blebs (double immunostain of apoptotic paraformaldehyde fixed cardiocytes; Figure 2B , orthogonal view). Furthermore, immunoprecipitation of apoptotic cardiocyte lysates by antiuPAR brought down a protein that was recognized by an affinity-purified antibody to Ro60 but not nl-IgG ( Figure  2C ). Affinity-purified anti-Ro52 or anti-La48 antibodies did not react with the anti-uPAR immunoprecipitate (Figure 2D ), indicating that uPAR shows preferential affinity toward the Ro60 component of the SSA/Ro-SSB/La ribonucleoprotein complex. Of note, however, immunoprecipitation of uPAR from a mixture of purified recombinant uPAR (1 g/mL) and Ro60 (1 g/mL) after incubation for 60 minutes at RT yielded solely uPAR (data not shown), suggesting that Ro60 and uPAR do not associate in vitro and that specific in vivo protein modifications and/or other cofactors are necessary for the 2 proteins to interact.
Blocking uPAR Reverses the Inhibitory Effect of Anti-Ro60 on Efferocytosis of Apoptotic Cardiocytes by Healthy Cardiocytes
Having established uPAR on the apoptotic cardiocyte surface and a potential interaction with the Ro60 component, the next set of experiments addressed whether uPAR serves as a "don't eat me" signal on the surface of apoptotic cells. 15 Consistent with a "don't eat me" signal, preincubation of apoptotic cardiocytes (which do not express Fc␣R) with either rabbit polyclonal or mouse monoclonal antibodies to uPAR enhanced uptake by healthy cardiocytes (54.5Ϯ4.9% rabbit isotype control versus 70Ϯ4% rabbit anti-uPAR; Pϭ0.005, nϭ4; Figure 3A ) and (61.25Ϯ4.7% mouse isotype control versus 77.5Ϯ6.4% mouse anti-uPAR; Pϭ0.009, nϭ4; Figure 3B ). No difference in apoptotic cell uptake was observed when the apoptotic cells were opsonized with mouse anti-HLA antibody (61.25Ϯ4.7% mouse isotype control versus 62Ϯ8% mouse anti-HLA; Pϭ0.7, nϭ4; Figure  3B ), confirming the specificity of the anti-uPAR antibody effect.
As previously demonstrated, 5 incubation with CHB-IgG results in an inhibition of efferocytosis (33Ϯ3% uptake CHB-IgG versus 58Ϯ4.5% nl-IgG; Pϭ0.002, nϭ6). To test whether uPAR is involved in the impaired clearance induced by CHB-IgG, apoptotic cardiocytes were initially treated with CHB-IgG and then subsequently incubated with 1 of the 2 different anti-uPAR antibodies. Murine anti-uPAR antibodies reversed the inhibitory effect of CHB-IgG on efferocytosis (63Ϯ9% uptake CHB-IgGϩanti-uPAR versus 33Ϯ3% CHB-IgG; Pϭ0.001, nϭ6; Figure 3C ). Similar results were obtained using the rabbit anti-uPAR antibodies (62Ϯ4% uptake CHBIgGϩanti-uPAR versus 35Ϯ5% CHB-IgG; Pϭ0.03, nϭ3). The "reversal" effect of anti-uPAR was further confirmed using the ScFv antibodies. Although both ScFv1 and ScFv2 recognize Ro60 in permeabilized cardiocytes, only ScFv1 binds the surface of apoptotic cardiocytes. 5 ScFv1, but not ScFv2, inhibited efferocytosis. Consistent with the reversal of CHB-IgG inhibition, murine anti-uPAR antibodies also abrogated the effects of ScFv1 (66Ϯ4% uptake anti-ScFv1ϩanti-uPAR versus 31Ϯ8% uptake ScFv1; Pϭ0.007, nϭ4; Figure 3D ). In contrast, the impaired clearance following incubation with ScFv1 remained unchanged by anti-HLA antibodies (34Ϯ2.5% uptake ScFv1ϩanti-HLA versus 36Ϯ4.7% ScFv1; Pϭ0.6, nϭ4), whereas murine anti-uPAR in the same set of experiments, again reversed the inhibitory effect of ScFv1 (60Ϯ6.45% uptake ScFv1ϩanti-uPAR versus 36Ϯ4.7% ScFv1; Pϭ0.002, nϭ4) ( Figure 3E ).
Binding of Anti-Ro60 Antibodies on the Apoptotic Surface Modulates uPAR Expression and Distribution
A molecular mechanism for the anti-uPAR rescue of antiRo60 -mediated inhibition of efferocytosis was further investigated. Preincubation of apoptotic cardiocytes with CHBIgG significantly increased the expression of uPAR over that observed after incubation with nl-IgG (58Ϯ8 MFU versus 31Ϯ7, respectively; Pϭ0.002, nϭ5), as determined by flow cytometry using rabbit anti-uPAR antibody to evaluate uPAR expression ( Figure 4A ). The increased expression was not attributable to cross-reactivity of the secondary antibody with the antibody used to preincubate the cells before uPAR antibody treatment (data not shown). A similar increase in uPAR expression was observed with 2 other CHB-IgG fractions known to contain antibodies to Ro60 (58.9Ϯ12 MFU CHB2-IgG versus 31Ϯ7 MFU nl-IgG; Pϭ0.009, nϭ5) and (52.5Ϯ13 MFU CHB2-IgG versus 31Ϯ7 MFU nl-IgG; Pϭ0.006, nϭ5). Specificity of the CHB-IgG was supported by the absence of any change in surface expression of uPAR In the graph summarizing collective FACS data, bars represent median of MFUϮSEM (nϭ5). B, Confocal microscopy demonstrates colocalization of uPAR (red) with Ro60 (green) on the surface of nonpermeabilized apoptotic cardiocytes in discrete membrane areas resembling apoptotic blebs. Cells were double-labeled with mouse monoclonal anti-uPAR and affinity-purified anti-Ro60 antibodies followed by Alexa Fluor-conjugated secondary antibodies. All fluorescence images taken were the maximum projection composites of at least 8 optical sections. The main image shown is 1 raw image stack. Orthogonal view is used see the inside of the main image stack (x-y). The 2 lines that cross in the x-y image are 2 cuts, revealing the side (x-z) and lower (y-z) view of the stack. Arrowheads point to the areas of colocalization. Cells are representative of data derived from 5 independent experiments. Scale bars represent 10 m. C, Triton X-100 -soluble whole cardiocyte lysates were immunoprecipitated with mouse species isotype control or mouse anti-uPAR antibody and immunoprecipitated proteins detected with affinity-purified anti-Ro60 antibody. Antibody reactivity at the expected (Ϸ60-kDa) region was observed (top), whereas no reactivity was detected with a control nl-IgG (middle). Confirmation of immunoprecipitated uPAR is shown at the bottom. D, In a separate experiment, anti-uPAR immunoprecipitant was not reactive with affinity-purified antibodies against Ro52 (top) or La48 (bottom).
following preincubation with RNP-IgG or anti-HLA (32Ϯ6 MFU RNP-IgG versus 31Ϯ7 nL-IgG, Pϭ0.8, nϭ5, 34Ϯ10 MFU anti-HLA versus 31Ϯ7 nL-IgG; Pϭ0.9, nϭ5; Figure  4A ). The specificity of the CHB-IgG was further confirmed using the monospecific anti-Ro60 ScFv antibodies ScFv1 and ScFv2. Preincubation with ScFv1, which binds apoptotic cells 5 increased the expression of uPAR compared to treatment with murine anti-uPAR alone (148Ϯ6 MFU versus 65Ϯ5, respectively; Pϭ0.05, nϭ3). Pretreatment with ScFv2, which does not bind apoptotic cells, 5 had no effect on the binding of anti-uPAR (68Ϯ8 MFU versus 65Ϯ5, respectively; Pϭ0.79, nϭ3; Figure 4B ). Similar results were obtained when evaluating uPAR expression using the rabbit polyclonal anti-uPAR antibodies (154.7Ϯ14 MFU anti-uPAR with ScFv1 preincubation versus 63.97Ϯ20 MFU uPAR with ScFv2 preincubation, respectively; Pϭ0.01, nϭ3; data not shown). No effect on uPAR expression was observed when cells were preincubated with chicken monoclonal ScFv antibodies against Ro52 (61Ϯ16 MFU versus 68Ϯ8 MFU, respectively; Pϭ0.67, nϭ3) or La48 (62.08Ϯ10 MFU versus 68Ϯ8, respectively; Pϭ0.8, nϭ3) ( Figure 4B, right) .
To investigate whether the molecular mechanism for the observed increase in uPAR expression was attributable to uPAR aggregation or clustering, apoptotic cells were treated with the traditional crosslinker DTSSP (1 mmol/L, 15 minutes, 4°C), and after lysis and SDS-PAGE, lysates were immunoblotted with anti-uPAR antibodies. As expected, a major 50-kDa band consistent with the molecular weight of uPAR was observed both in the presence and absence of DTSSP ( Figure 4C ). By contrast, a 100-kDa immunoreactive protein was detected only in the apoptotic cardiocytes treated with the crosslinker (Figure 4C ). To test whether a highmolecular-weight band could be induced by anti-Ro60 antibodies to the apoptotic cell surface, apoptotic cardiocytes were incubated with nl-IgG or CHB-IgG. Immunoblot of the lysates revealed a high-molecular-weight band at 100 kDa in addition to the 50-kDa uPAR in the CHB-IgG-treated cells, identical to that observed in apoptotic cardiocytes treated with the crosslinker DTSSP ( Figure 4D ). This highmolecular-weight band was not observed in apoptotic cells incubated with nl-IgG. Similar results were observed when apoptotic cardiocytes were preincubated with ScFv1 but not ScFv2 ( Figure 4E ).
Binding of CHB-IgG on the Apoptotic Surface Does Not Alter CD31, CD47, or Calreticulin Expression
The specificity of the CHB-IgG-dependent increase of uPAR expression was approached by evaluation of other surface molecules involved in cell recognition, such as calreticulin (CRT), CD31, and CD47. 33, 34 CRT, although present on living cells, serves as an "eat me" signal on the surface of apoptotic cells facilitating their clearance by engulfing cells. 35, 36 CD31, also referred to as PECAM-1, is a member of the immunoglobulin superfamily that functions as a "don't eat me" signal on living cells thus preventing their engulfment. During apoptosis this signal is disabled resulting in the removal of dying cells. 8 CD47, a membrane protein that serves as a receptor of thrombospondin, also functions as a Figure 3 . Blocking uPAR reverses the anti-Ro60 inhibition of efferocytosis. A and B, Apoptotic cardiocytes were treated with rabbit isotype IgG and rabbit anti-uPAR antibody (A) or mouse isotype control, mouse anti-uPAR antibody, or mouse anti-HLA antibody (B). Cells were subsequently washed, cocultured with healthy cardiocytes for 5 hour, washed, fixed and stained using TUNELperoxidase. Representative images of each condition are shown and numeric data summarized in the graphs presented below the images (nϭ4 for A and nϭ4 for B). The y axis represents the phagocytic index, which is expressed as the percentage of cardiocytes that contain at least 1 ingested apoptotic cardiocyte. C, Apoptotic cardiocytes were treated with nl-IgG, CHB-IgG, or mouse anti-uPAR antibody after preincubation with CHB-IgG. Cells were subsequently washed and cocultured with healthy cardiocytes for 5 hours, washed, fixed, and stained using TUNEL-peroxidase as in A. Representative images of cells treated with nl-IgG, CHB-IgG, or anti-uPAR antibody after preincubation with CHB-IgG are shown. Bottom, Graph summarizing the data (nϭ6). D, Apoptotic cardiocytes were treated with chicken monoclonal ScFv1, ScFv2, or antiuPAR antibody after preincubation with ScFv1 or ScFv2. Cells were subsequently washed and cocultured with healthy cardiocytes for 5 hours, extensively washed, fixed, and stained using TUNEL-peroxidase as in A. Representative image of ScFv1 or ScFv1 subsequently treated with uPAR antibody (left) and a graph summarizing the data are shown (nϭ4) (bottom). E, Apoptotic cardiocytes were treated with ScFv1 or mouse anti-uPAR or anti-HLA antibody after preincubation with ScFv1. Cells were subsequently washed and cocultured with healthy cardiocytes for 5 hours, washed, fixed, and stained using TUNEL-peroxidase as in A. Representative image of ScFv1, ScFv1 subsequently treated with uPAR antibody, or ScFv1 subsequently treated with HLA antibody is shown. A summary is presented in the graph (nϭ4).
"don't eat me" signal on living cells. 37 To address whether binding of CHB-IgG on the apoptotic surface alters expression of these molecules, apoptotic cardiocytes were preincubated with either nl-IgG or CHB-IgG and expression evaluated by flow cytometry. Treatment with the nl-IgG fraction or with CHB-IgG had no effect on the expression of CD31 (51Ϯ19 MFU versus 49Ϯ9, respectively; Pϭ0.6, nϭ4), CRT (55Ϯ9 MFU versus 56Ϯ3, respectively; Pϭ0.9, nϭ4), or CD47 (63Ϯ3 MFU versus 65Ϯ5 respectively; Pϭ0.9, nϭ4) ( Figure 5A ). In contrast to the effect of CHB-IgG and ScFv1 on inducing the formation of a high-molecular-weight antiuPAR immunoreactive conjugate, CHB-IgG did not induce 
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any apparent modifications of CRT, CD31, or CD47, as assessed by immunoblot ( Figure 5B ).
Binding of Anti-Ro60 on the Apoptotic Cardiocytes Increases Plasminogen Activation
Additional evaluation of the functional significance of the CHB-IgG-dependent increase of uPAR on the surface of the apoptotic cardiocytes focused on cell-associated fibrinolytic activity. Cell surface-associated uPA activity and subsequent plasminogen activation have been reported to be significantly elevated during apoptosis. 38 Based on flow cytometry, uPA was expressed on the surface of apoptotic cardiocytes ( Figure  6A ). To address whether CHG-IgG binding to apoptotic cardiocytes enhanced plasminogen activation by virtue of increased uPA activity, apoptotic cardiocytes were treated with either nl-IgG or CHG-IgG and then incubated with plasminogen. Plasminogen activation was monitored with a chromogenic assay. Apoptotic cardiocytes opsonized by CHB-IgG exhibited increased cell surface plasminogen activation compared to apoptotic cells incubated with nl-IgG Figure 6B ). To further investigate whether the anti-Ro60 -dependent increase in plasminogen activation on the apoptotic cardiocyte surface was attributable to uPAR-dependent uPA enzymatic activity, plasminogen assays were conducted in the presence of blocking antibodies to either uPA39 or uPAR40, each of which decrease uPA catalytic activity. 39, 40 Both the anti-uPA and anti-uPAR antibodies decreased the CHB-IgG dependent plasminogen activation (43.3Ϯ8.9% decrease by anti-uPA, Pϭ0.02, nϭ3; and 56.6Ϯ5.1% by anti-uPAR, Pϭ0.001, nϭ3; Figure 6C ). Further experiments addressed the dependence of anti-Ro60 binding to induce uPA activity and subsequent plasminogen activation. This was approached by evaluating the effects of ␤ 2 GPI because recently published data demonstrated that Ro60 functions as a novel receptor for ␤ 2 GPI and that ␤ 2 GPI competes with anti-Ro60 for binding to Ro60 at the cell surface. 41 Flow cytometry confirmed that preincubation of apoptotic cardiocytes with ␤ 2 GPI markedly decreased the binding of CHB-IgG to the apoptotic cardiocytes ( Figure 6C, inlay) . As predicted, the addition of ␤ 2 GPI before CHB-IgG attenuated plasminogen activation (56.4Ϯ23.4% inhibition, Pϭ0.02, nϭ3; Figure 6C ).
Discussion
Exaggerated apoptosis has been proposed as a pathological link between anti-SSA/Ro-SSB/La antibodies and the development of cardiac conduction defects during the second trimester of human pregnancy and remodeling of the human fetal heart. Although apoptosis provides a molecular mechanism for facilitating accessibility of an otherwise sequestered autoantigen to an extracellular cognate antibody, paradoxi- Light gray trace represents anti-uPA, whereas dark trace is isotype control. B, Nonpermeabilized apoptotic cardiocytes were treated with nl-IgG, CHB-IgG, ScFv1, or ScFv2 for 30 minutes and plated in triplicate in a 96-well plate, and plasminogen activation was determined using a chromogenic assay as described in Methods. The y axis represents plasminogen activation (uPA enzymatic activity units) (nϭ5). C, Nonpermeabilized apoptotic cardiocytes were treated with CHB-IgG followed by antiuPA or anti-uPAR or preincubated with ␤ 2 GPI (5 g/mL) and subsequently treated with CHB-IgG. Plasminogen activation was measured as in B. The y axis represents the percentage inhibition of plasminogen activation in each condition compared to plasminogen activation by CHB-IgG (nϭ3). Also shown is a representative histogram of nonpermeabilized apoptotic cardiocytes incubated with nl-IgG or CHB-IgG in the presence or absence of ␤ 2 GPI (5 g/mL) for 1 hour. Light trace represents CHB-IgG, and dark trace represents nl-IgG. ␤ 2 GPI inhibits the binding of CHB-IgG as previously described. 41 Briassouli et al CHB: Relationship Between uPA/uPAR and Anti-Rocally, the opsonization by bound antibody inhibits efferocytosis by neighboring cardiocytes. The present study provides experimental evidence for a novel effect of maternal antiRo60 binding which may contribute to the perturbed clearance. Specifically, apoptotic cardiocytes incubated with antiRo60 antibodies demonstrate an increased and potentially modified distribution of uPAR expression, which serves as a "don't eat me" signal. The effect on expression was also observed with a single chain fragment variant monoclonal antibody recognizing Ro60, indicating that bivalency is not required. This contrasts with other autoantibodies, such as anti-antiphospholipid antibodies, in which bivalency is critical to mediate crosslinking of surface membrane protein and subsequent downstream signaling events. 42, 43 Preincubation of the apoptotic cardiocytes with an antibody to uPAR restores clearance despite opsonization by anti-Ro60 antibodies. An additional consequence of the interplay between uPAR and anti-Ro60 binding is the enhancement of uPA protease activity as demonstrated by the generation of plasmin. This increase in protease activity may further promote an amplification cycle of injury by cleaving ␤ 2 GPI, rendering it unable to displace anti-Ro60 from binding to the apoptotic surface. 41 Figure 7 summarizes these proposed molecular events.
The initial function ascribed to uPAR was the concentration of urokinase-dependent proteolytic activity on the surface of cells, which would increase the potential of cells to move and migrate through barriers. 16 Later, it became clear that uPAR is also a signaling receptor. 19 Applicable to the present work, previous studies have demonstrated that the plasminogen cascade is involved in apoptosis, especially on uPA-expressing cells. 38, 44 Apoptosis results in a marked increase in the surface expression of uPA and plasminogen binding and activation. 38 It is hypothesized that during apoptosis, this is required for the activation of proteases, as well as the degradation of cellular targets.
The participation of uPAR in regulating efferocytosis has only recently been described. Park et al addressed this role in a system exploiting a uPAR knockout mouse model. 15 The main focus of their model was to assess uPAR as a factor in the resistance of viable cells to phagocytic uptake. Macrophages from deficient mice demonstrated an enhanced ability to engulf viable wild-type neutrophils. In the reciprocal experiment, uPAR deficiency on viable neutrophils resulted in enhanced uptake by wild-type macrophages. Of greatest relevance to the present study, incubation of apoptotic wildtype neutrophils with soluble uPAR (which presumably results in increased adhesion of uPAR) resulted in the reduction of efferocytosis by the macrophages. The study did not examine whether wild-type macrophages ingested knockout apoptotic neutrophils more readily than wild-type neutrophils. This scenario would be predicted based on the findings of the present study in which opsonization of apoptotic cardiocytes by anti-Ro60 increased uPAR expression and decreased apoptotic uptake by healthy cardiocytes. D'Mello et al also addressed the influence of uPAR on efferocytosis, exploiting cell lines overexpressing uPAR and transient gene transfer. 14 In this work, the emphasis was on the phagocytosing cell. Expression of uPAR promoted engulfment of apoptotic T cells but not viable T cells. Although ostensibly at odds with the proposed role of uPAR as a negative regulator ("don't eat me" signal) of efferocytosis, these findings do not preclude an effect of uPAR on the apoptotic cell per se.
The precise mechanism by which anti-Ro60 binding leads to increased expression of uPAR as assessed by anti-uPAR Figure 7 . This illustration demonstrates our present interpretation. During physiological apoptosis in cardiac development, Ro60 translocates to the cell surface. There is a balance between anti-Ro60 and ␤ 2 GPI binding to Ro60. The binding of anti-Ro60 increases uPAR expression. This blocks efferocytosis by healthy cardiocytes and also results in stimulation of uPA enzymatic activity, which generates plasmin. In turn, plasmin cleavage of ␤ 2 GPI favors increased anti-Ro60 binding. Thus, an amplification cycle is generated which results in accumulation of apoptotic cardiocytes, as demonstrated in histological evaluation of CHB hearts. 12 antibodies is not known. However, the possibility that antiRo60 binding leads to a de novo increase in uPAR protein synthesis was considered unlikely because the cells were undergoing apoptosis. A more biologically plausible hypothesis is that anti-Ro60 binding induces uPAR aggregation or clustering. GPI-linked proteins such as uPAR are typically found in lipid rafts of plasma membranes 45 and clustering of uPAR controls its partitioning to these rafts. 46 Within these rafts, GPI-linked proteins show lateral diffusional mobility and can be crosslinked by antibodies yielding protein aggregates. [47] [48] [49] [50] [51] The data presented herein support this possibility because uPAR distribution on the surface of the apoptotic cell was modified by the binding of anti-Ro60 antibodies, as evidenced by the appearance of a high-molecular-weight conjugate ( Figure 4D and 4E ). This effect was not dependent on antibody bivalency because monoclonal single-chain fragment variants against Ro60 were also able to mediate uPAR aggregation in the absence of secondary crosslinking reagents. Similar findings have been reported for TRAIL ScFvs that induce TRAIL-receptor 2 (TR2) oligomerization. 52 Because uPAR exists in both monomers and oligomers on the cell surface, it is possible that anti-Ro60 antibody binding leads to increased clustering of either preassembled uPAR oligomers or induces uPAR monomer clustering. The composition and protein identities within this complex are presently being characterized and should further clarify the sequence of observed events.
There is precedent for modification of surface molecules during apoptosis, which serve to facilitate recognition and clearance by neighboring cells. For example, CRT on the apoptotic cell surface is redistributed in patches rich in phosphatidylserine and the ganglioside GM133. 53 However, in the studies reported herein, uPAR was distinct from other "eat me" and "don't eat me" molecules, such as CRT, CD31, and CD47, because there was no increase in their expression following anti-Ro60 binding. Moreover, uPAR has been reported to be anchored to the actin cytoskeleton, 54 rearrangements of which are critical to the process of proper apoptotic body formation. Thus, altered expression and distribution of uPAR by anti-Ro60 could perturb the physiological process of surface membrane blebbing that occurs during apoptosis. 55 The significance and necessity of a direct interaction between uPAR and Ro60 in mediating the decrease of efferocytosis and increase in plasminogen activation is not clear. Although the experimental evidence demonstrates colocalization and an affinity between the 2 proteins, a direct interaction was not observed in vitro using recombinant proteins. As mentioned above, uPAR has been shown to bind a variety of proteins through its lateral movement in the cell membrane. 49 -51 However, unambiguous evidence for these interactions is not available. 13 The finding that Ro60 but not Ro52 or La48 interact with uPAR, as evidenced by the immunoprecipitation experiments presented suggests that a Ro60-dependent uPAR regulation results in the functional effects observed in the presence of anti-Ro60 antibodies.
Of additional relevance to the pathogenesis of CHB is the well-characterized function of uPAR described above, in which it serves as a cofactor for the generation of the serine protease plasmin from plasminogen activation by uPA. The data presented herein suggest that anti-Ro60, by virtue of increased uPAR expression, leads to increased uPA activity and subsequent plasminogen activation. The mechanism by which an increase in the expression of uPAR results in enhanced uPA activity may involve uPAR protein aggregation, tightly focusing uPA molecules on the surface of the apoptotic bleb, which would result in more efficient and condensed enzymatic activity.
A further potential link of the uPA/uPAR system to the pathogenesis of CHB relates to the observation by Reed et al that the plasma protein ␤ 2 GPI binds Ro60 (amino acid residues 82 to 244) on the surface of apoptotic cells and prevents the formation of pathogenic anti-Ro60 antibodyapoptotic cell immune complexes. 41, 56 As expected, preincubation of ␤ 2 GPI prevented binding of anti-Ro60 to the apoptotic cardiocytes and decreased the generation of plasmin. The corollary has also been demonstrated in that plasmin cleavage of the ␤ 2 GPI hydrophobic loop (Lys317-Thr318) abrogates the binding of ␤ 2 GPI to apoptotic cell membranebound Ro60. Thus, maternal anti-Ro60 IgG binds to apoptotic cells in the presence of plasmin cleaved ␤ 2 GPI under conditions where an equivalent concentration of native ␤ 2 GPI completely inhibited this immune complex formation. 57 Effectively this creates an amplification loop in which antiRo60 binding generates plasmin, which cleaves ␤ 2 GPI, facilitating further binding by anti-Ro60 antibodies. Integrating these observations with those of the experiments presented herein suggests the following scenario. The initial binding of anti-Ro60 to Ro60 (not masked by ␤ 2 GPI) induces the increased distribution, expression, and function of uPAR and the generation of plasmin, the consequence of which is cleavage of ␤ 2 GPI and further accessibility of surface Ro60 to maternal antibody ( Figure 7) . In summary, uPAR may be a critical linchpin in the pathological cascade to CHB by virtue of its increased activity following anti-Ro60 binding to apoptotic cells, which results in 2 pathogenic situations fueling a vicious amplification loop to inflammation/fibrosis. One is a "don't eat me" signal to the surrounding healthy cardiocytes that are attempting bland clearance of remodeling cells, and the other is the generation of plasmin, which cleaves ␤ 2 GPI, effectively eliminating this protective barrier to antibody binding. Collectively, the data in this study provide a molecular basis by which maternal autoantibodies (at least to the Ro60) contribute to impaired clearance of apoptotic cells through increasing uPAR-dependent "don't eat me" signals and support the newly identified involvement of uPAR in efferocytosis. Exploring the role of uPAR on the healthy engulfing cells and the participation of other components of the uPAR system namely uPA and PAI-1 in this CHB model merit further investigation.
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